α-Conotoxin Decontamination Protocol Evaluation: What Works and What Doesn’t by Turner, Matthew W. et al.
Boise State University
ScholarWorks
Chemistry Faculty Publications and Presentations Department of Chemistry and Biochemistry
9-1-2017
α-Conotoxin Decontamination Protocol
Evaluation: What Works and What Doesn’t
Matthew W. Turner
Boise State University
John R. Cort
Pacific Northwest National Laboratory
Owen M. McDougal
Boise State University
This document was originally published in Toxins by Multidisciplinary Digital Publishing Institute (MDPI). This work is provided under a Creative
Commons Attribution 4.0 license. Details regarding the use of this work can be found at: http://creativecommons.org/licenses/by/4.0/. doi: 10.3390/
toxins9090281
toxins
Article
α-Conotoxin Decontamination Protocol Evaluation:
What Works and What Doesn’t
Matthew W. Turner 1, John R. Cort 3 and Owen M. McDougal 2,*
1 Biomolecular Sciences Graduate Programs, Boise State University, Boise 83725, ID, USA;
matthewturner1@u.boisestate.edu
2 Department of Chemistry and Biochemistry, Boise State University, Boise 83725, ID, USA
3 Biological Sciences Division, Pacific Northwest National Laboratory, Richland 99354, WA, USA;
John.Cort@pnnl.gov
* Correspondence: owenmcdougal@boisestate.edu; Tel.: +1-208-426-3964
Academic Editor: Luis M. Botana
Received: 11 August 2017; Accepted: 9 September 2017; Published: 14 September 2017
Abstract: Nine publically available biosafety protocols for safely handling conotoxin peptides were
tested to evaluate their decontamination efficacy. Circular dichroism (CD) spectroscopy and mass
spectrometry (MS) were used to assess the effect of each chemical treatment on the secondary and
primary structure of α-CTx MII (L10V, E11A). Of the nine decontamination methods tested, treatment
with 1% (m/v) solution of the enzymatic detergent Contrex™ EZ resulted in a 76.8% decrease in
α-helical content as assessed by the mean residue ellipticity at 222 nm, and partial peptide digestion
was demonstrated using high performance liquid chromatography mass spectrometry (HPLC-MS).
Additionally, treatment with 6% sodium hypochlorite (m/v) resulted in 80.5% decrease in α-helical
content and complete digestion of the peptide. The Contrex™ EZ treatment was repeated with three
additional α-conotoxins (α-CTxs), α-CTxs LvIA, ImI and PeIA, which verified the decontamination
method was reasonably robust. These results support the use of either 1% Contrex™ EZ solution or 6%
sodium hypochlorite in biosafety protocols for the decontamination of α-CTxs in research laboratories.
Keywords: conotoxin; select agent; circular dichrosim (CD) spectroscopy; mass spectrometry (MS);
high performance liquid chromatography (HPLC); peptide decontamination; biosafety protocols
1. Introduction
The venom of predatory marine snails from the genus Conus is comprised of as many as 1000
distinct neurologically active peptides [1]. These small disulfide rich peptide toxins are referred
to as conotoxins (CTxs). There are approximately 700 Conus species, resulting in the staggering
potential that 70,000–100,000 unique CTxs exist [1–3]. CTxs vary in their mechanism of action, and
many have been found to modulate ion channels. These include α-CTxs which inhibit ligand gated
nicotinic acetylcholine receptors (nAChRs), δ-CTxs which inhibit inactivation of voltage-dependent
sodium channels, ω-CTxs which inhibit N-type voltage-dependent calcium channels, and κ-CTxs
which inhibit potassium channels [2]. CTxs have a remarkable diversity of pharmacological functions,
which provides valuable insight for the development of unique ligands for laboratory and therapeutic
applications. Because CTxs represent extremely specific molecular probes, they are routinely used by
researchers as a tool to study and differentiate between closely related biological receptor subtypes.
The specificity and potency of CTxs that leads to their utility in the laboratory and their therapeutic
potential also makes them potentially lethal if mishandled. The U.S. Army has calculated the LD50
of CTxs to be as low as 5 µg/kg [4,5]. For this reason, certain α-CTxs have been designated as
Biological Select Agents or Toxins (Select Agents) by the U.S. Department of Health and Human
Services [6]. Systematic investigation into methods of inactivation of α-CTxs is required in order to
Toxins 2017, 9, 281; doi:10.3390/toxins9090281 www.mdpi.com/journal/toxins
Toxins 2017, 9, 281 2 of 10
establish safe laboratory practices that ensure the health and well-being of researchers using these
hazardous materials.
The current study is limited to α-CTxs. A survey of literature accessible in the National
Center for Biotechnology Information (NCBI) pubmed resource shows that 74% (3385 of the 4564) of
published works on CTxs are studies involving α-CTxs. The methods for safely decontaminating and
neutralizing α-CTx waste vary greatly in universities where CTx research is conducted; this study
evaluated currently employed biosafety protocols used in university research laboratories. Several
current decontamination protocols for CTxs rely on procedures demonstrated to be effective on
low molecular weight toxins of biological origin [7–9]. Other protocols use reactive disinfectants
such as glutaraldehyde and/or formaldehyde; however, this treatment typically requires hazardous
waste disposal of the resulting material. Some biosafety protocols exploit the susceptibility of
CTxs to treatment with reducing agents, like dithiothreitol or β-mercaptoethanol, followed by thiol
alkylation [10]. However, these decontamination protocols require specific reaction conditions to be
effective, e.g., prolonged incubation at elevated temperatures or protection from light, making these
methods difficult to scale-up for releases of large amounts of CTx, or decontamination of large surface
areas. Destruction of the CTxs through the hydrolytic activity of concentrated (5–10 M) acids or bases
is also impractical to safely scale-up to remedy large-scale spills [11]. Therefore, a rigorous study of
a wide array of decontamination techniques was undertaken to determine the best method to safely
and effectively mitigate the toxic hazard presented by α-CTxs as typically used in a practical research
laboratory setting. The purpose of this study was to establish a decontamination protocol to efficiently
disrupt the α-helical content and digest α-CTx by chemical treatment. To this end, the effects of various
classes of chemicals, including oxidizing agents, reducing agents, crosslinking agents, and Contrex™
EZ, a commercially marketed protease enzyme-detergent mixture, were studied for their impact on
the secondary and primary structure of α-CTx using circular dichroism (CD) spectroscopy and mass
spectrometry (MS), respectively. Several α-CTxs were selected for this study due to their sequence
similarity and disulfide connectivity to CTxs designated as Select Agents by the U.S. Department of
Health and Human Services. The sequence of the α-CTxs used in this study and the U.S. Department
of Health and Human Services definition for the primary sequence of a CTx select agent are shown in
Table 1.
Table 1. Amino acid sequences for the α-CTxs used in this study and CTx select agent sequence motif.
For the α-CTxs in Table 1 all cysteine residues are present as cystines with the 1st and 3rd cysteine
and the 2nd and 4th cysteine joined through disulfide bonds. For the select agent, the XN amino acid
represents the following: X1 may be any or no residue; X2 is N or H; X3 is R or K; X4 is N, H, K, R, Y,
F or W; X5 is Y, F or W; X6 is S, T, E, D, N, or Q; and X7 is any or no residue. Emboldened residues
indicate conserved elements of the select agent motif.
Name Sequence Ref.
LvIA G C C S H P A C N V D H P E I C [12]
MII (L10V, E11A) G C C S N P V C H V A H S N L C [13]
ImI G C C S D P R C A W R - - - - C [14]
PeIA G C C S H P A C S V N H P E L C [15]
Select Agent X1 C C X2 P A C G X3 X4 X5 X6 - C X7 [6]
2. Results
2.1. Secondary Structure Analysis of Treated Conotoxin
To determine the effect of chemical treatment on the secondary structure of α-CTx MII (L10V,
E11A), α-helical content was estimated from the measured ellipticity at 222 nm. Typical CD spectra for
chemical treatments of α-CTx MII (L10V, E11A) are shown in Figure 1.
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Figure 1. CD spectra for native α-CTx MII (L10V, E11A) and α-CTx MII (L10V, E11A) following 
chemical treatment for 15 min with 8 M urea, 6 M HCl, 6% sodium hypochlorite, 1% Contrex™ EZ, 
and 500 μM glutathione. 
The ability of chemical agents to disrupt the secondary structure of α-CTx MII (L10V, E11A) is 
summarized in Table 2. Untreated α-CTx MII (L10V, E11A) was estimated to have an α-helical 
content of 43.8 ± 2.3%; this is in close agreement with previously reported values for wild type and 
mutant α-CTx MII [16]. Based on CD analysis of treated peptides, the most-efficient chemical 
treatments for disrupting the secondary structure of α-CTx MII (L10V, E11A) were 8 M urea (91.2% 
decrease), 6 M HCl (81.5% decrease), 6% (m/v) sodium hypochlorite (80.5% decrease), and 1% (m/v) 
Contrex™ EZ (76.8% decrease). Chemical crosslinking with 2% (m/v) glutaraldehyde did not decrease 
the α-helical content, but interestingly, treatment with a combination of glutaraldehyde and 
formaldehyde seemed to disrupt secondary structure, with a 33.5% decrease in α-helical content. 
Treatment with ozone, hydrogen peroxide, and dithiothreitol (DTT) resulted in no significant change 
in α-helical content, and glutathione was only modestly effective at disrupting secondary structure, 
with a demonstrated decrease of 9.4%.  
Table 2. Summary of the estimated α-helical content of α-CTx MII (L10V, E11A) prior to and 
following chemical treatment at 15 min reaction time. Samples were run in triplicate with the average 
± standard deviation shown. The α-helical content represents the percent decrease as compared to the 
control peptide, which has α-helical content of 43.8 ± 2.3%. 
Treatment α-Helical Content Δ α-Helical Content  
No Treatment  43.8 ± 2.3% NA 
8 M Urea  3.9 ± 0.7% 91.2% 
6 M Hydrochloric Acid 8.1 ± 0.4% 81.5% 
6% Sodium Hypochlorite  8.6 ± 0.4% 80.5% 
1% Contrex™ EZ 10.2 ± 1.8% 76.8% 
1% Glutaraldehyde/1% Formaldehyde  29.1 ± 2.3% 33.5% 
500 μM Glutathione 39.6 ± 1.4% 9.4% 
10 mM Dithiothreitol 43.5 ± 4.8%  No Change 
2% Glutaraldehyde  44.1 ± 1.1% No Change 
Ozone  46.7 ± 2.5% No Change 
10% Hydrogen Peroxide/UV  47.0 ± 7.0% No Change 
2.2. Primary Structure Analysis of Treated Conotoxin 
Figure 2 shows liquid chromatography (LC) chromatograms of untreated α-CTx MII (L10V, 
E11A) (a), and α-CTx MII (L10V, E11A) following treatment with Contrex™ EZ (b), 
formaldehyde/glutaraldehyde (c), and sodium hypochlorite (d). The molecular weight observed for 
Figure 1. CD spectra for native α-CTx MII ( V, E 1A) and α-CTx MII (L10V, E11A) following
chemical treatmen for 15 min with 8 M urea, Cl, 6% sodium hyp chlorite, 1% Contrex™ EZ,
and 500 µM glutathione.
The ability of chemical agents to disrupt the secondary structure of α-CTx MII (L10V, E11A) is
summarized in Table 2. Untreated α-CTx MII (L10V, E11A) was estimated to have an α-helical content
of 43.8 ± 2.3%; this is in close agreement with previously reported values for wild type and mutant
α-CTx MII [16]. Based on CD analysis of treated peptides, the most-efficient chemical treatments for
disrupting the secondary structure of α-CTx MII (L10V, E11A) were 8 M urea (91.2% decrease), 6 M
HCl (81.5% decrease), 6% (m/v) sodium hypochlorite (80.5% decrease), and 1% (m/v) Contrex™ EZ
(76.8% decreas ). Chemical cros linking with 2% (m/v) glutaraldehyde did not decrease the α-helical
content, but interestingly, treatment with a combination of glutaraldehy e a d form lde yde seemed
to disrupt secondary structure, with a 33.5% decrease in α-helical content. Treatment with ozone,
hydrogen peroxide, and dithiothreitol (DTT) resulted in no significant change in α-helical content,
and glutathione was only modestly effective at disrupting secondary structure, with a demonstrated
decrease of 9.4%.
Table 2. Summary of the estimated α-helical c ntent of α-CTx MII (L10V, E11A) prior to and following
chemical treatment at 15 min reaction time. Samples were run in triplicate with the average ± standard
deviation shown. The α-helical content represents the percent decrease as compared to the control
peptide, which has α-helical content of 43.8 ± 2.3%.
Treatment α-Helical Content ∆ α-Helical Content
No Treatment 43.8 ± 2.3% NA
8 M Urea 3.9 ± 0.7% 91.2%
6 M Hydrochloric Acid 8.1 0.4% 81.5%
6% Sodium Hypochlorite 8.6 0.4% 80.5%
% Contrex™ EZ 10.2 1.8% 76.8%
1% Glutaraldehyde/1% Formaldehyde 29.1 ± 2.3% 33.5%
500 µM Glutathione 39.6 ± 1.4% 9.4%
10 mM Dithiothreitol 43.5 ± 4.8% No Change
2% Glutaraldehyde 44.1 ± 1.1% No Change
Ozone 46.7 ± 2.5% No Change
10% Hydrogen Peroxide/UV 47.0 ± 7.0% No Change
2.2. Primary Structure Analysis of Treated Conotoxin
Figure 2 shows liquid chromatography (LC) chromatograms of untreated α-CTx MII
(L10V, E11A) (a), and α-CTx MII (L10V, E11A) following treatment with Contrex™ EZ (b),
formaldehyde/glutaraldehyde (c), and sodium hypochlorite (d). The molecular weight observed
for untreated α-CTx MII (L10V, E11A) was 1639.618 Da, with a doubly charged ion observed at
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820.314 m/z and a triply charged ion observed at 547.211 m/z (Figure 3a). Contrex™ EZ treatment
resulted in digested peptide fragments of diminished molecular weights, including ions observed at
982.378 m/z, 883.308 m/z and a singly charged ion of 869.341 m/z shown in Figure 3b. Formaldehyde
and glutaraldehyde are aggressive carbonyl reagents that react with proteins at primary amines.
Glutaraldehyde alone, or in combination with formaldehyde, is commonly used as a disinfectant.
Formaldehyde/glutaraldehyde treatment provided a modest increase in observed molecular weight
to 1775.673 Da, supported by the increase from m/z 820.314 to 888.342 in the doubly charged ion
(Figure 3d). The shift in m/z from 820.314 to 888.342 in the doubly charged ion corresponds to a
mass shift of 136 Da in α-CTx MII (L10V, E11A). This result is consistent with the formation of imine
bonds by two glutaraldehyde molecules forming intra-peptide crosslinks. The mass addition of each
glutaraldehyde crosslink (C5H8) is 68 Da. The mass increase of 136 Da in the doubly charged mass
spectrum of glutaraldehyde treated peptide can be attributed to the addition of C10H16 to the molecular
formula of α-CTx MII (L10V, E11A). Inter-peptide crosslinking between several α-CTx MII (L10V,
E11A) molecules was not observed. Sodium hypochlorite treatment entirely digested α-CTx MII (L10V,
E11A), and no discernable peaks in the mass range 250–2900 Da were observed in the mass spectrum.
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Figure 2. Liquid chromatography chromatograms of (a) native α-CTx MII (L10V, E11A); (b) Contrex
™ EZ treated α-CTx MII (L10V, E11A); (c) formaldehyde/glutaraldehyde treated; and (d) sodium
hypochlorite treated.
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3. Discussion 
Near-UV CD spectroscopy indicated that DTT effectively reduced the disulfide bonds of α-CTx 
MII (L10V, E11A), as shown by the disappearance in the band around 270 nm (Supplemental Figure 
S1). The near UV absorption of the disulfide bond occurs near 260 nm and is generally quite weak 
[17,18]. Reduction of the disulfide bonds was confirmed by MS as shown by the 4 Da shift in Figure 
3c; the 4 Da shift is observed as a 2 Da shift from 820.314 to 822.325 in the doubly charged ion, 
compared to m/z for the untreated α-CTx MII (L10V, E11A) (Figure 3a). Interestingly, reduction of 
the disulfide framework did not disrupt the secondary structure of the peptide, and would therefore 
not be expected to guarantee inactivation of biological potency. If the CTx retains native structure, 
despite reduced disulfide bonds, the activity of the toxin must be assumed to be intact.  
Ozonolysis of peptides has been shown to affect amino acids with aromatic side chains and 
histidine [19]. α-CTx MII (L10V, E11A) contains two histidine residues, and exposure to ozone for 24 
h resulted in a mass shift of 16 Da in ~30% of the peptides (Supplemental Figure S2). Treatment with 
O3 did not affect the secondary structure of α-CTx MII (L10V, E11A), leading to the conclusion that 
ozonolysis is an ineffective decontamination method. Hydrogen peroxide treatment followed by 
exposure to ultraviolet light generates hydroxyl radicals with potential to cleave peptide bonds. 
However, hydrogen peroxide treatment did not alter the secondary or primary structure of α-CTx 
MII (L10V, E11A), as evidenced by the absence of either significant decrease in α-helical content by 
CD, or mass shift by MS (data not shown).  
Figure 3. MS data for various α-CTx MII (L10V, E11A) samples where: (a) untreated α-CTx MII (L10V,
E11A) measured by direct infusion; and (b) Contrex™ EZ treated samples in which digested peptide
fragments of reduced MW are observed by LC-MS (The spectrum corresponds to the major peak
observed in Figure 2b with a retention time 10.4 min.); (c) DTT treated sample measured by direct
infusion with a mass shift of 4 Da, observed as a 2 Da shift from 820.314 to 822.325 in the doubly charged
ion, indicating that disulfide bonds were reduced; and (d) formaldehyde/glutaraldehyde treated
samples in which covalent modifications increase the MW of α-CTx MII (L10V, E11A), as observed by
an in rease from m/z 820.314 to 888.342 in the doubly c arg d ion. The spectrum corresponds to the
major peak observed in Figure 2c with a retention time 12.9 min.
3. Discussion
Near-UV CD spectroscopy indicated that DTT effectively reduced the disulfide bonds of α-CTx
MII (L10V, E11A), as shown by the disappearance in the band around 270 nm (Supplemental Figure S1).
The near UV absorption of the disulfide bond occurs near 260 nm and is generally quite weak [17,18].
Reduction of the disulfide bonds was confirmed by MS as shown by the 4 Da shift in Figure 3c; the 4 Da
shift is ob erved as a 2 Da shift from 820.314 to 822.325 in the doubly charged ion, compared to
m/z for the untreated α-CTx MII (L10V, E11A) (Fi ure 3a). Interestingly, reduction of he disulfide
framework did not disr pt the secondary structure of the peptide, and would therefore not be expected
to guarantee inactivation of biological potency. If the CTx retains native structure, despite reduced
disulfide bonds, the activity of the toxin must be assumed to be intact.
Ozonolysis of peptides has been shown to affect amino acids with aromatic side chains and
histidine [19]. α-CTx MII (L10V, E11A) contains two histidine residues, and exposure to ozone for
24 h resulted in a mass shift of 16 Da in ~30% of the peptides (Supplemental Figure S2). Treatment
with O3 did not affect the secondary structure of α-CTx MII (L10V, E11A), leading to the conclusion
that ozonolysis is an ineffective econtamination method. Hydrog n peroxide tre tment followed
by exposu e to ultraviolet light generates hydroxyl radicals with potential to cleave peptide bonds.
However, hydrogen peroxide treatment did not alter the secondary or primary structure of α-CTx MII
(L10V, E11A), as evidenced by the absence of either significant decrease in α-helical content by CD,
or mass shift by MS (data not shown).
Treatment of α-CTx MII (L10V, E11A) with 8 M urea was effective at disrupting the secondary
structure. The peptide samples treated with 8 M urea were diluted immediately prior to CD
measurement in order to obtain each spectrum. Although treatment with urea did disrupt secondary
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structure, it did not alter the primary structure of α-CTx MII (L10V, E11A), as determined by MS.
To be an effective decontamination method, additional treatment following urea induced peptide
denaturation would be required. Treatment with 6 M hydrochloric acid was effective at denaturing
α-CTx MII (L10V, E11A), but this is not a practical protocol for ameliorating spills due to highly
hazardous properties.
Two chemical treatment options, sodium hypochlorite and Contrex™ EZ, were identified as the
most effective and applicable laboratory decontamination methods reviewed in this investigation.
Sodium hypochlorite (6% (m/v)) treatment caused complete disruption of secondary structure and
digestion of α-CTx MII (L10V, E11A). This result may be due to excess sodium hydroxide present in
commercial Clorox used to stabilize the sodium hypochlorite in the product, or because of oxidative
cleavage of peptide bonds by sodium hypochlorite. Sodium hypochlorite has a pungent odor and
acts as a strong oxidizer that can react unfavorably with common laboratory chemicals, however,
bleach is ubiquitously available, inexpensive, and frequently used as a disinfectant in laboratories.
Sodium hypochlorite (6% (m/v)) appears to be an effective method to use in biosafety protocols for the
decontamination of α-CTxs in research laboratories.
For α-CTx decontamination, Contrex™ EZ lacks the negative characteristics of bleach, but
retains desired activity. Contrex™ EZ contains an anionic surfactant detergent as well as Esperase,
a non-specific endo-peptidase that has broad specificity and high activity in pH range 8–12 [20,21].
Thus, we sought to explore how robust chemical treatment of α-CTx with Contrex™ EZ was using
α-CTxs PeIA, LvIA, and ImI. The result was consistent with Contrex™ EZ treatment of α-CTx MII
(L10V, E11A) as confirmed by CD spectroscopy and MS (Figure 4). The α-helical content for α-CTx
PeIA was observed to decrease from 36.6 ± 3.3% in native peptide, to 11.1 ± 7.7% in the Contrex™
EZ treated sample. Similarly, the α-helical content for α-CTx LvIA decreased from 37.4 ± 2.1% in
the native peptide, to 10.1 ± 0.1% in the Contrex™ EZ treated sample. α-CTx ImI does not have the
typical α-helical region found in the other α-CTxs used in this study, so the α-helical content was not
calculated for this sample. However, the CD spectrum of α-CTx ImI did indicate a change in secondary
structure upon treatment with Contrex™ EZ.
The secondary structure of each Contrex™ EZ treated α-CTx was shown to be disrupted,
but not destroyed, and digestion produced peptide fragments of reduced molecular weight by mass
spectrometry, not complete digestion. It is possible for miniaturized or partially digested peptide to
maintain undesirable activity. Assessment of partially digested peptide activity was not evaluated.
It is thus recommended that 6% sodium hypochlorite be used when handling highly potent α-CTxs to
ensure complete digestion.
The results of this study indicate the use of 1% Contrex™ EZ (m/v) solution may be suitable for
inclusion in biosafety protocols requiring decontamination of dilute solutions of α-CTxpeptides
(e.g., HPLC waste, peptide synthesizer waste, filtrate, etc.), laboratory spills of dilute peptides,
or cleaning of equipment exposed to trace amounts of α-CTxs. In situations requiring decontamination
of concentrated solution or solid peptide, or highly potent α-CTx (e.g., select agent α-CTx), 6% sodium
hypochlorite has been confirmed to be the recommended method to ensure inactivation. The scope of
this study was limited to the evaluation of decontamination procedures for α-CTxs. The recommended
decontamination procedures may not apply to all CTxs, particularly those with significant differences
in disulfide framework, solubility, or peptide size.
In laboratories where use of bleach is acceptable, sodium hypochlorite 6% (m/v) solution proved
to be an effective chemical treatment for α-CTxs. Alternatively, treatment with 1% solution of Contrex™
EZ resulted in a 76.8% decrease in α-helical content and digestion of α-CTx MII (L10V, E11A) into
smaller peptide fragments as demonstrated by mass spectrometry. The results of this investigation
indicate that partial digestion occurs within the first 15 min of treatment. For liquid chemical waste
decontamination, all liquid waste containing α-CTxs, including HPLC waste, may be stored in 4 L
carboys, to which 40 g of Contrex™ EZ powder should be added to achieve ~1% solution (% w/v).
A 4 lb container of Contrex™ EZ can be purchased from fishersci.com for $54.00 USD, and 121 oz of
Toxins 2017, 9, 281 7 of 10
Clorox HE performance bleach can be purchased from Amazon.com for $15.75 USD. Decontamination
of a 4 L bottle of waste containing 100 µg conotoxin for every 1 mL of solution will cost on the order of
$1.20 USD for Contrex EZ as compared to $1.60 USD for bleach. In the studies reported herein, the
decontamination methods were tested on α-CTx containing solutions of high peptide content (1.7 mg
of α-CTx MII (L10V, E11A) per 1.0 mL) and low chemical treatment concentration (1% Contrex™ EZ
solution). A recommended time for decontamination of liquid waste is a minimum of one hour to
ensure more than adequate time for α-CTx degradation.
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Figure 4. LC-MS chromatograms of (a) native α-CTx ImI, (b) Contrex™ EZ treated α-CTx ImI, (d) 
native α-CTx LvIA, (e) Contrex™ EZ treated α-CTx LvIA, (g) native α-CTx PeIA and Contrex™ EZ 
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Figure 4. LC-MS chromatograms of (a) nativeα-CTx ImI; (b) Contrex™ EZ treatedα-CTx ImI; (d) native
α-CTx L IA; (e) Contrex™ EZ treated α-CTx LvIA; (g) native α-CTx PeIA and Contrex™ EZ treated
α-CTx P IA (h). CD spectra are also shown for native nd treated α-CTx ImI (c); α-CTx L I (f);
and α-CTx PeIA (i). LC-MS data demonstrate the efficacy of Contr at eliminating the native
α-CTx, and CD spectra confirm that Contrex™ EZ effectively disrupts the secondary structure of
the α-CTxs.
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4. Materials and Methods
4.1. Solvents and Reagents
Chemical treatments were prepared from 8 M urea, 30% hydrogen peroxide (m/v), 12 M
hydrochloric acid (HCl), 50% glutaraldehyde (m/v), 37% formaldehyde (m/v), dithiothreitol (DTT),
and glutathione purchased from Fisher Scientific (Pittsburgh, PA, USA). Contrex™ EZ powdered
enzymatic detergent was purchased from Decon Labs (King of Prussia, PA, USA). Household Clorox
bleach was used for the 6% sodium hypochlorite. High pressure liquid chromatography (HPLC)
mobile phase consisted of 18 MΩ H2O and HPLC grade formic acid and acetonitrile (>99% purity,
Fisher Scientific). All α-CTxs used in this study were purchased from CS Bio (Menlo Park, CA, USA)
at a purity of >95%.
4.2. Chemical Treatments
The following treatment conditions were used: 8 M urea, 6% sodium hypochlorite, 1% Contrex™
EZ solution (m/v), 10% hydrogen peroxide (m/v) with UV irradiation, gaseous ozone, 6 M
hydrochloric acid, 2% glutaraldehyde (m/v), 1% formaldehyde (m/v)/1% glutaraldehyde (m/v),
10 mM dithiothreitol, and 500 µM glutathione. For each of these treatments, the reaction was allowed to
proceed for 15 min prior to sample dilution and analysis of secondary structure using CD spectroscopy.
Prior to analysis by HPLC-MS, Contrex™ EZ, the reaction was quenched and samples were purified
using a Pierce Strong Cation Exchange Spin Column (Thermo Fisher Scientific, Waltham, MA, USA),
a wash buffer composed of 25 mM sodium acetate, pH 5.5, and an elution buffer of 25 mM sodium
acetate, 1 M NaCl, at pH 5.5. All other reactions were quenched and samples were purified using
Pierce PepClean™ C18 Spin Columns (Thermo Fisher Scientific, Waltham, MA, USA) activated with
50% methanol (v/v), and a wash buffer composed of 5% acetonitrile (v/v) and 0.5% trifluoroacetic acid
(v/v), and an elution buffer of 70% acetonitrile (v/v). Ozone gas was generated with a Villa 1000 ozone
generator from SD International, Inc. (Tallahassee, FL, USA) operated at an output of 1800 mg ozone
per hour. The reaction was performed with a 50 µM solution of α-CTx MII (L10V, E11A) exposed to
flowing ozone captured in a custom-made reaction vessel for up to 24 h. α-CTx MII (L10V, E11A)
treated with 10% hydrogen peroxide was exposed to UV irradiation in a biosafety hood with a UV
lamp operating at an intensity of 125 µW/cm2 at a distance of ~1 m for 20 min.
4.3. Circular Dichroism Spectroscopy
CD spectra were recorded on a Jasco J-810 spectropolarimeter (Jasco, Inc., Easton, MD, USA) with
a cell path length of 1 cm at room temperature in a nitrogen atmosphere. Scans were acquired from
190 to 250 nm and 250 to 300 nm for far-UV and near-UV, respectively. The bandwidth of 1 nm, a speed
of 50 nm/min, and a resolution of 0.5 nm were used. A total of 5 scans per sample were averaged,
baselines were subtracted, and each sample was run in triplicate. A final concentration of 50 µM
and 500 µM were used for far-UV and near-UV scanning wavelengths, respectively. Analysis and
processing of data were carried out with the Jasco system software and Microsoft Excel. Mean
residue ellipticity (θMRE, in deg × cm2 × dmol−1) for each spectrum was calculated from the
formula θMRE = θ/(10 Crl), where θ is the measured ellipticity in millidegrees, Cr is the molar
concentration, and l is the path length in centimeters. The α-helical content was estimated from the
formula θMRE = −30300fH − 2340, where fH is the fraction of α-helical content (fH × 100, expressed
as a percentage) calculated from the θMRE at 222 nm, is a widely used proxy for helical secondary
structure that is useful to assess disruption of the secondary structure, as is performed here [22].
The final concentration of the chemical treatments varied and were determined individually as the
maximum concentration at which a suitable signal at 222 nm could be obtained without noise affecting
the reliability of the measured signal. The final concentration of each chemical treatment at the time it
was measured is summarized in Supplemental Table S1.
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4.4. High Performance Liquid Chromatography-Mass Spectrometry
Untreated and treated α-CTxs were analyzed by HPLC-MS using an ultra-high resolution
Quadrupole Time of Flight (QTOF) instrument (Bruker maXis, Bruker Corporation, Billerica, MA, USA)
by direct injection to the MS or by HPLC-MS. The electrospray ionization (ESI) source was operated
under the following conditions: positive ion mode; nebulizer pressure: 0.4 or 1.2 Bar; flow rate of
drying gas (N2): 4 or 8 L/min; drying gas temperature: 200 ◦C; voltage between HV capillary and
HV end-plate offset: 3000 V to −500 V; mass range was set from 250 to 2900 m/z; and the quadrupole
ion energy was 4.0 eV. Low concentration ESI tuning mix (Agilent Technologies, Santa Clara, CA,
USA) was used to calibrate the system in the mass range. Samples analyzed by direct infusion with a
syringe pump at a flow rate of 240 µL/h. HPLC separation was achieved using a Dionex UltiMate®
3000 uHPLC system (Dionex Corporation, Sunnyvale, CA, USA) equipped with a Thermo Acclaim™
120 C18 column (2.1× 150 mm, 3 µm) (Thermo Fisher Scientific, Waltham, MA, USA). The mobile phase
was 0.1% formic acid in water (Buffer A) and acetonitrile (Buffer B) with a flow rate of 0.3 mL/min.
A linear gradient method was used to separate the mixture starting at 5% acetonitrile and ending at
65% acetonitrile over 25 mi. The sample injection volume was 1 µL. Data were analyzed using the
Compass Data Analysis software package (Bruker Corporation, Billerica, MA, USA).
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/9/281/s1.
Figure S1: Near UV data of untreated and DTT treated α-CTx MII (L10V, E11A) is shown. Figure S2: α-CTx
MII (L10V, E11A) exposed to ozone for 24 h. Table S1: Concentration of chemicals when analyzed by far-UV
CD spectroscopy.
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